{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:33:18Z","timestamp":1778509998318,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.bbmt.2017.01.071","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T13:15:54Z","timestamp":1484226954000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab"],"prefix":"10.1016","volume":"23","author":[{"given":"Rebecca A.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Neumeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharat","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Teusink-Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parinda A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.01.071_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1704795","article-title":"A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders","volume":"35","author":"Shenoy","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0020","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2005-05-1819","article-title":"Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis","volume":"107","author":"Cooper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bmt.2008.151","article-title":"Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome","volume":"42","author":"Bhatla","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1705926","article-title":"Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen","volume":"41","author":"Hansen","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0035","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","volume":"21","author":"Marsh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Gungor","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0045","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.bbmt.2012.05.006","article-title":"Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution","volume":"18","author":"Law","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/146532401317070899","article-title":"Pharmacokinetics of CAMPATH-1H in BMT patients","volume":"3","author":"Rebello","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbmt.2015.10.022","article-title":"Comparison of subcutaneous versus intravenous alemtuzumab for graft-versus-host disease prophylaxis with fludarabine\/melphalan-based conditioning in matched unrelated donor allogeneic stem cell transplantation","volume":"22","author":"Patel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0065","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0070","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbmt.2013.11.005","article-title":"Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies","volume":"20","author":"Lane","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0080","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jcyt.2013.05.016","article-title":"Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery","volume":"15","author":"Gartner","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-1759(01)00556-7","article-title":"Pharmacokinetics of CAMPATH-1H: assay development and validation","volume":"260","author":"Rebello","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0095","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","article-title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils","volume":"88","author":"Elsner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0100","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","article-title":"Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, & lymphocyte recovery following alemtuzumab, fludarabine & melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.01.071_bib0115","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117301969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117301969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:25Z","timestamp":1761058705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117301969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1083879117301969"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.01.071","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.01.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}